Kenneth Marek

30.9k citations

189 papers · 13.5k indexed · 3 hit papers · h-index 52

Impact in

Neurology top 0.02%
- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
Cellular and Molecular Neuroscience top 0.2%
- Genetic Neurodegenerative Diseases
- Nuclear Receptors and Signaling

Papers in

Neurology 115
- Parkinson's Disease Mechanisms and Treatments 103
- Neurological disorders and treatments 82
- Botulinum Toxin and Related Neurological Disorders 15
Cellular and Molecular Neuroscience 44
- Neuroscience and Neuropharmacology Research 12
- Nuclear Receptors and Signaling 12

Co-authors: John Seibyl Daniela Berg Werner Poewe Matthew Stern Anthony E. Lang Thomas Gasser C. Warren Olanow Wolfgang H. Oertel
Journals: Movement Disorders (27 papers)Neurology (25 papers)Alzheimer s & Dementia (11 papers)Journal of Nuclear Medicine (8 papers)Journal of Parkinson s Disease (8 papers)
Partner nations: United States Germany Canada

In The Last Decade

Kenneth Marek

184 papers receiving 13.3k citations

Hit Papers

align trajectories log scale

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease 2024 · 56 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Nature Medicine
2015 Movement Disorders
2015 Movement Disorders

Peers

Countries citing papers authored by Kenneth Marek

Since Specialization

Citations

This map shows the geographic impact of Kenneth Marek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Marek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Marek more than expected).

Fields of papers citing papers by Kenneth Marek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Marek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Marek. The network helps show where Kenneth Marek may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kenneth Marek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kenneth Marek Line = papers co-authored together Kenneth Marek links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Toward a biological definition of neuronal and glial synucleinopathies Nature Medicine ·Claudio Soto, Brit Mollenhauer, Oskar Hansson, Un Jung Kang, Roy N. Alcalay, David G. Standaert, Claudia Trenkwalder, Kenneth Marek, Douglas Galasko, Kathleen L. Poston	2025	5
2	Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial Nature Medicine ·Gennaro Pagano, Annabelle Monnet, 赵瑞希, Benjamin Ribba, Hanno Svoboda, Thomas Kustermann, Tanya Simuni, Ronald B. Postuma, Nicola Pavese, Fabrizio Stocchi, Kathrin Brockmann, Roya Mehdizade, Gülcan Gencer, Paulo Fontoura, Rachelle S. Doody, Geoffrey A. Kerchner, О. Аймаганбетова, Kenneth Marek, Azad Bonni, Tania Nikolcheva, (unknown), (unknown)	2024	14
3	Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older Neurology ·Michael C. Brumm, Kerri A. Pierz, David-Erick Lafontant, Chelsea Caspell‐Garcia, Christopher S. Coffey, Andrew Siderowf, Kenneth Marek	2023	25
4	LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts npj Parkinson s Disease ·Kalpana Merchant, Tanya Simuni, Ivelisse Garris, Chelsea Caspell‐Garcia, Michael C. Brumm, Kelly Nudelman, Yrd. Doç. Dr. Alpaslan Okur, F. Hsieh, Roy N. Alcalay, Christopher S. Coffey, Lana M. Chahine, Tatiana Foroud, Andrew Singleton, Daniel Weintraub, Samantha J. Hutten, Todd Sherer, Brit Mollenhauer, Andrew Siderowf, Caroline M. Tanner, Kenneth Marek, (unknown)	2023	12
5	Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression Journal of Parkinson s Disease ·Michael C. Brumm, Andrew Siderowf, Tanya Simuni, C. Dauccia, Seung Ho Choi, Chelsea Caspell‐Garcia, Lana M. Chahine, Brit Mollenhauer, Tatiana Foroud, Douglas Galasko, Kalpana Merchant, Vanessa Arnedo, Samantha J. Hutten, Ahmed Samir Abdul, Kathleen L. Poston, Caroline M. Tanner, Daniel Weintraub, Karl Kieburtz, Kenneth Marek, Christopher S. Coffey, (unknown)	2023	25
6	Proposal for a Biologic Staging System of Parkinson’s Disease Journal of Parkinson s Disease ·Lana M. Chahine, Kalpana Merchant, Andrew Siderowf, Todd Sherer, Caroline M. Tanner, Kenneth Marek, Tanya Simuni	2023	45
7	Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial The Lancet Neurology ·Nir Giladi, Roy N. Alcalay, Gary Cutter, Thomas Gasser, Tanya Gurevich, Günter U. Höglinger, Kenneth Marek, Claudio Pacchetti, Anthony H.V. Schapira, Clemens R. Scherzer, Tanya Simuni, Pascal Minini, S. Pablo Sardi, Michel Peterschmitt	2023	38
8	Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohorts npj Parkinson s Disease ·Ф.Л. Перепадя, William A Meyer, Rachneet Kaur, Sayed Hadi Hashemi, Hampton L. Leonard, Hirotaka Iwaki, Mary B. Makarious, Kimberley J. Billingsley, Sara Bandrés‐Ciga, Lana Sargent, Alastair J. Noyce, Ali Daneshmand, Cornelis Blauwendraat, Kenneth Marek, Sonja W. Scholz, Andrew Singleton, Mike A. Nalls, Roy H. Campbell, Faraz Faghri	2022	50
9	PPMI 2.O New Science/New Cohorts - Transforming PPMI (2490) Neurology ·Kenneth Marek, Andrew Siderowf, Karl Kieburtz, Christopher S. Coffey, Tatiana Foroud, Lana M. Chahine, Kathleen L. Poston, Brit Mollenhauer, Douglas Galasko, Vanessa Arnedo, Tanya Simuni, Caroline M. Tanner	2020	4
10	[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer’s disease European Journal of Nuclear Medicine and Molecular Imaging ·Sandra Sanabria Bohórquez, Jan Mařı́k, Annie Ogasawara, Jeff N. Tinianow, Herman Gill, Olivier Barret, Gilles Tamagnan, David Alagille, Gai Ayalon, Paul T. Manser, Thomas Bengtsson, Michael E. Ward, Simon‐Peter Williams, Geoffrey A. Kerchner, John Seibyl, Kenneth Marek, Robby M. Weimer	2019	82
11	Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures Journal of Parkinson s Disease ·Lana M. Chahine, (unknown), Andrew Siderowf, Janel Barnes, Elisabeth Bauch, Chelsea Caspell‐Garcia, Tanya Simuni, Christopher S. Coffey, Douglas Galasko, Brit Mollenhauer, Vanessa Arnedo, Ani Grace Kalaimathi, Mark Frasier, Caroline M. Tanner, Karl Kieburtz, Kenneth Marek	2019	14
12	Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers Molecular Imaging and Biology ·Cristian Constantinescu, Cédric Tresse, Ming‐Qiang Zheng, B. Eng, Vincent M. Carroll, Karli DeRego, David Alagille, Christine Sandiego, Caroline Papin, Kenneth Marek, John Seibyl, Gilles Tamagnan, Olivier Barret	2018	52
13	MDS clinical diagnostic criteria for Parkinson's disease Movement Disorders ·Ronald B. Postuma, Daniela Berg, Matthew Stern, Werner Poewe, C. Warren Olanow, Wolfgang H. Oertel, José Á. Obeso, Kenneth Marek, Irene Litvan, Anthony E. Lang, Glenda M. Halliday, Christopher G. Goetz, Thomas Gasser, Bruno Dubois, Piu Chan, Bastiaan R. Bloem, Charles H. Adler, Günther Deuschl Hit paper breakdown →	2015	4841
14	Assessment of Parkinson disease progression using 123- I I-Ioflupane SPECT: Update from the Parkinson Progression Marker Initiative Trial (I11-5C) Neurology ·John Seibyl, Danna Jennings, Kenneth Marek	2015	1
15	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease Movement Disorders ·Daniela Berg, Ronald B. Postuma, Bastiaan R. Bloem, Piu Chan, Bruno Dubois, Thomas Gasser, Christopher G. Goetz, Glenda M. Halliday, John Hardy, Anthony E. Lang, Irene Litvan, Kenneth Marek, José Á. Obeso, Wolfgang H. Oertel, C. Warren Olanow, Werner Poewe, Matthew Stern, Günther Deuschl	2014	341
16	Brain distribution of BZM055, an analog of fingolimod (FTY720), in human Multiple Sclerosis Journal ·Gilles Tamagnan, Adriana Tavares, Olivier Barret, D Alagille, John Seibyl, Kenneth Marek, R. P. Maguire, Emmanuelle Briard, Robert Schmouder, Korneĭchuk Vv, Danna Jennings	2012	10
17	Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study Movement Disorders ·Andrew Siderowf, Danna Jennings, Shirley Eberly, David Oakes, Keith A. Hawkins, S. M. Motonaga, Matthew B. Stern, Kenneth Marek, (unknown)	2012	144
18	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts Movement Disorders ·Connie Marras, Michael McDermott, Kenneth Marek, Paula A. Rochon, Gary Naglie, Caroline M. Tanner, Alice Rudolph, Ira Shoulson, Anthony E. Lang, (unknown)	2011	17
19	Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: preliminary results in four patients. PubMed ·D. Eugene Redmond, Richard J. Robbins, Frederick Naftolin, Kenneth Marek, Timothy Vollmer, Csaba Léránth, R.H. Roth, Lawrence H. Price, Albert Gjedde, B.S. Bunney	1993	13
20	Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Future^a Annals of the New York Academy of Sciences ·D. Eugene Redmond, Robert H. Roth, Dennis D. Spencer, Frederick Naftolin, Csaba Léránth, Richard J. Robbins, Kenneth Marek, John D. Elsworth, Kimberlee J. Sass, Jane R. Taylor, John R. Sladek	1993	11

About Kenneth Marek

Kenneth Marek is a scholar working on Neurology, Cellular and Molecular Neuroscience, Neurology, Cognitive Neuroscience and Sensory Systems, having authored 189 papers that have together received 13.5k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (103 papers), Neurological disorders and treatments (82 papers), Alzheimer's disease research and treatments (23 papers), Medical Imaging Techniques and Applications (17 papers), Autism Spectrum Disorder Research (16 papers), Botulinum Toxin and Related Neurological Disorders (15 papers), Neuroscience and Neuropharmacology Research (12 papers) and Nuclear Receptors and Signaling (12 papers). The work is most often cited by research in Neurology (9.9k citations), Cellular and Molecular Neuroscience (3.5k citations), Neurology (1.4k citations), Sensory Systems (514 citations) and Cognitive Neuroscience (1.8k citations). Kenneth Marek has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include John Seibyl, Daniela Berg, Werner Poewe, Matthew Stern, Anthony E. Lang, Thomas Gasser, C. Warren Olanow, Wolfgang H. Oertel, Ronald B. Postuma and Irene Litvan. Their work appears in journals such as Movement Disorders, Neurology, Alzheimer s & Dementia, Journal of Nuclear Medicine and Journal of Parkinson s Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact